CCD 1042, MD 9150000, Mepalon 1042, SPT3162 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 152 | ＰＣＤＨ19関連症候群 | 4 |
152. ＰＣＤＨ19関連症候群
臨床試験数 : 10 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004496-12-GB (EUCTR) | 14/01/2020 | 18/11/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 70 | Phase 3 | United States;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Australia;Denmark;Germany;Netherlands | ||
| 2 | EUCTR2018-004496-12-HU (EUCTR) | 13/01/2020 | 04/11/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Australia;Denmark;Germany;Netherlands | ||
| 3 | EUCTR2018-004496-12-NL (EUCTR) | 23/09/2019 | 05/06/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 30 | Phase 2 | United States;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Belgium;Poland;Australia;Denmark;Netherlands;Germany | ||
| 4 | EUCTR2018-004496-12-PL (EUCTR) | 01/08/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | NA | Female: yes Male: no | 30 | Phase 2 | United States;Czechia;Spain;Ireland;Italy;United Kingdom;France;Hungary;Poland;Belgium;Australia;Denmark;Germany;Netherlands |